Analystreport

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.

PROGENICS PHARMACEUTICALS  (PGNX) 
Last progenics pharmaceuticals earnings: 8/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: progenics.com